fbpx

Ian Rosenthal, MD, PhD

Board-Certified Dermatopathologist

Bio

Dr. Ian M. Rosenthal, MD, PhD, is an experienced Board-Certified Dermatopathologist and has been providing dermatopathology services since 2015.

Dr. Rosenthal completed his Fellowship in Dermatopathology at Memorial Sloan-Kettering Cancer Center and New York Presbyterian Hospital-Weill Cornell Medical College. Prior to Fellowship he completed his Residency in Anatomic Pathology at The Johns Hopkins Hospital. He earned his Doctor of Medicine degree from The Johns Hopkins University School of Medicine.

Dr. Rosenthal also received his Doctor of Philosophy at The Johns Hopkins University School of Public Health, where he was responsible for developing the first new clinically approved drug combination for tuberculosis in over 50 years. He also completed postdoctoral work at Johns Hopkins University School of Medicine with a focus on the experimental chemotherapy of tuberculosis. Additionally, Dr. Rosenthal has authored over 40 dermatopathology publications and abstracts throughout his career and is also passionate about teaching and mentorship. He has led numerous teaching and tutorial sessions with Cornell Dermatology Residents and Johns Hopkins University medical students.

When he is not working, Dr. Rosenthal can be found spending time with his wife and two boys, playing classical guitar, and cooking new recipes from around the world. Dr. Rosenthal is thrilled to continue to provide patient centered dermatopathology for all Optima Dermatology patients.

Quick Facts

  • Board-Certified Dermatopathologist
  • Anatomic Pathology Residency at The Johns Hopkins Hospital
  • Fellowship in Dermatopathology at Memorial Sloan-Kettering Cancer Center and New York Presbyterian Hospital-Weill Cornell Medical College
  • Bachelor of Science in Molecular Biology and Botany from the University of Wisconsin-Madison
  • Doctor of Medicine degree from The Johns Hopkins University School of Medicine
  • Received PhD for developing the first new clinically approved drug combination for tuberculosis in over 50 years at The Johns Hopkins University School of Public Health